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Abstract
Background: The Mannose-binding lectin (MBL) pathway of complement plays a pivotal role in the pathogenesis of
ischemia/reperfusion (I/R) injury after experimental ischemic stroke. As comparable data in human ischemic stroke are
limited, we investigated in more detail the association of MBL deficiency with infarction volume and functional outcome in a
large cohort of patients receiving intravenous thrombolysis or conservative treatment.
Methodology/Principal Findings: In a post hoc analysis of a prospective cohort study, admission MBL concentrations were
determined in 353 consecutive patients with an acute ischemic stroke of whom 287 and 66 patients received conservative
and thrombolytic treatment, respectively. Stroke severity, infarction volume, and functional outcome were studied in
relation to MBL concentrations at presentation to the emergency department. MBL levels on admission were not influenced
by the time from symptom onset to presentation (p=0.53). In the conservative treatment group patients with mild strokes
at presentation, small infarction volumes or favorable outcomes after three months demonstrated 1.5 to 2.6-fold lower
median MBL levels (p=0.025, p=0.0027 and p=0.046, respectively) compared to patients with more severe strokes.
Moreover, MBL deficient patients (,100 ng/ml) were subject to a considerably decreased risk of an unfavorable outcome
three months after ischemic stroke (adjusted odds ratio 0.38, p,0.05) and showed smaller lesion volumes (mean size 0.6 vs.
18.4 ml, p=0.0025). In contrast, no association of MBL concentration with infarction volume or functional outcome was
found in the thrombolysis group. However, the small sample size limits the significance of this observation.
Conclusions: MBL deficiency is associated with smaller cerebral infarcts and favorable outcome in patients receiving
conservative treatment. Our data suggest an important role of the lectin pathway in the pathophysiology of cerebral I/R
injury and might pave the way for new therapeutic interventions.
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Introduction
Complement mannose-binding lectin (MBL), a member of the
collectin subfamily of C-type lectins, is a key component of innate
immunity [1]. Besides its important contribution to host defense
against pathogens, MBL is also involved in the binding and removal
of apoptotic cells leading to complement activation in an antibody-
and complement C1q independent manner [2,3]. In humans
polymorphisms within the coding and promoter regions of the
MBL2 gene lead to functional MBL deficiency in up to one third of
the Caucasian population characterized by reduced levels of
circulating functional MBL multimers [4]. During lifetime individ-
ual MBL serum levels remain remarkably stable highlighting the
dominating influence of genetics as compared to environmental
factors. Even during acute inflammation, low MBL serum
concentrations are predictive for moderate to severe deficiency
[5]. However, there is considerable interindividual MBL level
variability (up to ten-fold) in people with the same genotype.
Numerous studies have acknowledged the deleterious effects of
complement activation in the pathogenesis of ischemia/reperfu-
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activation of the coagulation cascade and direct tissue damage. In
particular, several lines of evidence from murine models, one
human experimental model, and one clinical trial emphasize a
central and active role for complement MBL in aggravating tissue
damage after I/R injury of the heart [7,8,9,10], kidney [11], gut
[12,13], and skeletal muscle [14]. With respect to cerebral I/R
injury results from two recent experimental studies demonstrate
that MBL deficiency or inhibition leads to diminished complement
C3 deposition and neutrophil influx into the affected brain region
and is associated with smaller infarct volumes and better functional
outcomes in mice [15,16]. In humans comparable data are scarce.
Activation of the complement system has been confirmed in three
clinical studies after acute ischemic stroke [17,18,19]. Regarding
the effect of MBL, Cervera et al. could demonstrate a significant
association of genetically defined MBL deficiency with favorable
outcome after three months, though in a small cohort that
included a considerable number (19%) of hemorrhagic stroke
patients [15]. Moreover, the impact of MBL deficiency on the
outcome after thrombolytic treatment was not analyzed. Throm-
bolytic agents cause a striking systemic activation of the
complement system [20], but data on the role of MBL in cerebral
I/R injury after thrombolysis is lacking. Hence, the aim of this
study was to investigate the impact of functional MBL deficiency
in human acute ischemic stroke in a prospective cohort of
consecutive patients receiving intravenous thrombolysis or con-
servative treatment according to the European Guidelines [21].
Methods
Ethics Statement
The study had been approved by the local ethical committee at
the University Hospital of Basel and all participants or their
representative gave written informed consent for the study.
Participants
We conducted a post hoc analysis of a previously published,
prospective cohort study at the University Hospital Basel, Basel,
Switzerland consisting of 359 patients presenting to the emergency
department with an acute ischemic stroke within 72 hours after
symptom onset between November 2006 and November 2007.
Patients were classified as either receiving conservative treatment
(including monitoring of blood pressure, oxygen saturation, serum
glucose, temperature and neurological symptoms, early mobiliza-
tion, prevention of complications, and treatment of hypoxia,
hyperglycemia, pyrexia and dehydration) or intravenous throm-
bolysis according to the European Guidelines [21]. A complete
description of the study including information about clinical work-
up, recorded clinical variables, blood-sampling and neuroimaging
has been reported previously [22].
Definitions of endpoints
The primary endpoint for this analysis was favorable functional
outcome (score 0 or 1) on the modified Rankin scale (mRS) within
90 days after admission. Secondary endpoints included functional
status as assessed by the Barthel Index (BI) at day 90 (favorable
outcome was defined as BI.=95%), death from any cause within
a 90-day follow-up, severity of stroke as assessed by the National
Institutes of Health Stroke Scale (NIHSS) score on admission, and
infarction volume assessed by magnetic resonance imaging (MRI)
during initial work-up (categorized according to Katan and
colleagues [22]). MRI scans were available in 157/297 and 42/
66 patients receiving conservative and thrombolytic treatment,
respectively.
MBL level analysis
For the MBL analysis serum samples drawn immediately on
admission to our emergency department (within 0–72 hours after
symptom onset) prior to any diagnostic imaging or thrombolytic
treatment were available from 353 of 359 patients, of whom 287
and 66 individuals received conservative and intravenous (i.v.)
thrombolytic treatment, respectively. For the i.v. treatment group
we analyzed additional samples 24 and 72 hours after admission
which were available from 56 patients. Quantification of
functional MBL was performed by an investigator blinded to
any patient data using a commercially available Sandwich-ELISA
Kit (MBL Oligomer ELISA KIT 029, Lucerna Chem, Luzern,
Switzerland) as described previously [23]. Since the definition of
functional MBL deficiency is likely to be dependent on the clinical
setting, we first analyzed the predefined endpoints in relation to
MBL levels. Only in a secondary analysis functional MBL
deficiency was defined as serum levels #100 ng/ml, as this cut-
off has been shown to discriminate reasonably well between
individuals with or without homozygosity for MBL variant alleles
[24] and to be clinical relevant in human cardiac IR injury [8]. As
our study was not powered to identify significant differences in
mortality with regard to the predefined MBL cut-off, patients were
stratified according to MBL level tertiles in the analysis of Kaplan-
Meier survival curves.
Statistical analysis
Differences in patient characteristics and outcome measures
according to treatment and MBL serostatus were analyzed using
the Fisher’s exact test or the Mann-Whitney-U-Test where
appropriate. Due to the non-Gaussian distribution of human
MBL levels two-group comparisons of MBL concentrations were
performed using a Mann-Whitney-U-test, whereas for multigroup
comparison a Kruskal-Wallis one-way analysis of variance or
Friedman test was applied where appropriate. Dunn’s post test was
used to correct p-values for multiple comparisons. Mortality was
analyzed by the log-rank test. Kaplan-Meier estimates were
plotted over the observation period of 90 days.
Stepwise logistic regression models were used to estimate the
association of MBL levels on predefined endpoints in multivariate
analyses after adjustment for covariables being present prior to the
ischemic event with univariate p values less than 0.1. Covariables
tested in univariate analyses included patient age, sex, vital
parameters and Charlson comorbidity index on admission, history
of vascular risk factors, time from symptom onset to admission,
and body mass index. All testing was two-tailed, and p values less
than 0.05 were considered to be statistically significant.
Results
Patients’ characteristics
Admission serum samples were available from 353 of 359
consecutive patients with an acute ischemic stroke and a complete
follow-up, of whom 287 and 66 patients underwent conservative
treatment and intravenous thrombolysis, respectively. The base-
line and outcome characteristics of the whole study cohort and
classified according to the therapeutic intervention are summa-
rized in Table 1. In summary, patients in the conservative
treatment group were older (median age of 76 (interquartile range
(IQR) 66–83) vs. 71 (IQR 57–70), p,0.001), suffered from more
comorbidities (median Charlson Index of 1 (IQR 0–2) vs. 0 (IQR
0–1), p=0.002), and presented with a less severe stroke (median
NIHSS score of 4 (IQR 2–8) vs. 12 (IQR 7–19), p,0.001),
whereas unadjusted outcomes after 90 days were similar (data not
shown).
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On admission the median MBL serum level of all patients
included in this study was 1482 ng/ml (IQR 411–2675 ng/ml),
and 37 of 353 (10%) individuals showed levels below 100 ng/ml,
thereby closely resembling frequency distributions observed in the
general population [4,24]. Furthermore, initial MBL levels were
similar in patients presenting to our emergency department within
0–3 (median 1502 ng/ml), 3–12 (median 1388 ng/ml), 12–24
(median 1768 ng/ml) and 24–72 hours (median 1607 ng/ml) after
symptom onset (p=0.53), as was the case in the two treatment
groups. Sequential analysis of MBL serum levels in the
thrombolysis group revealed stable MBL levels during the first
24 hours after administration of thrombolytic agents (admission:
median 1500 (IQR 490–2250) ng/ml; after 24 hours: median
1610 (IQR 459–2259) ng/ml). However, a significant increase in
MBL levels occurred after five days (median 2167 (IQR 548–3281)
ng/ml, p,0.001 for the comparison of admission vs. day 5),
reflecting a mild acute phase reaction. As expected from previous
studies, this increase was only observed in MBL sufficient patients,
whereas MBL levels remained constant in MBL deficient patients
[5].
Conservative treatment group
Association with functional outcome and death after
ischemic stroke. Uni- and multivariate analysis of the
primary endpoint showed that MBL levels were significantly
associated with functional outcome after three months in this
treatment group: Patients with a complete recovery (i.e., a mRS of
0 or 1) had lower MBL levels than individuals with an unfavorable
outcome (median MBL level 1116 (IQR 370–2524) vs. 1713 (IQR
420–3018) ng/ml, p=0.046, Figure 1). After adjusting for
potential confounders being present prior to the ischemic event
MBL levels remained independently associated with an
unfavorable outcome three months after ischemic stroke (OR
1.23, 95% CI 1.02–1.48, for every 1000 ng/ml increase,
p=0.036) in addition to age (Table 2).
To confirm the influence of MBL levels on functional recovery
after ischemic stroke a second outcome measure (Barthel Index)
Table 1. Baseline characteristics of the study population.
Baseline characteristics
All
(n=353)
Conservative treatment
(n=287)
Thrombolysis
(n=66)
Age (median, IQR) 75 (63–82) 76 (66–83) 71 (57–79)
Female sex, n (%) 145 (41) 123 (43) 22 (33)
MBL in ng/ml (median, IQR) 1482 (411–2675) 1461 (408–2857) 1498 (475–2250)
NIHSS on admission (median, IQR) 5 (2–10) 4 (2–8) 12 (7–19)
Charlson index (median, IQR) 1 (0–2) 1 (0–2) 0 (0–1)
Vascular risk factors
Hypertension, n (%) 269 (76) 220 (77) 49 (74)
D.m., n (%) 69 (20) 61 (21) 8 (12)
Coronary heart disease, n (%) 88 (25) 74 (26) 14 (21)
Hypercholesterolemia, n (%) 91 (26) 76 (26) 15 (23)
Atrial fibrillation, n (%) 74 (21) 63 (22) 11 (17)
Prior stroke, n (%) 86 (24) 74 (26) 12 (18)
Family history of stroke and/or myocardial
infarction, n (%)
105 (30) 86 (30) 19 (29)
Stroke etiology*
Small-vessel occlusion, n (%) 55 (15) 51 (18) 4 (6)
Large-artery atherosclerosis, n (%) 64 (18) 53 (18) 11 (17)
Cardioembolism, n (%) 130 (37) 100 (35) 30 (45)
Other - determined, n (%) 17 (5) 11 (4) 6 (9)
Undetermined, n (%) 87 (25) 72 (25) 15 (23)
Stroke syndrome
TACS, n (%) 40 (11) 20 (7) 20 (30)
PACS , n (%) 160 (45) 125 (44) 35 (53)
LACS , n (%) 72 (20) 67 (23) 5 (8)
POCS , n (%) 81 (23) 75 (26) 6 (9)
Outcome measures
mRS day 90 (median, IQR) 2 (1–4) 2 (1–4) 2 (1–5)
mRS 0–1 day 90, n (%) 161 (46) 135 (47) 26 (40)
Death, n (%) 42 (12) 32 (11) 10 (15)
Abbreviations: mRS=modified Rankin Scale; IQR=interquartile range; NIHSS=National Institutes of Health Stroke Scale; TACS=total anterior circulation syndrome;
PACS=partial anterior circulation syndrome; LACS=lacunar syndrome; POCS=posterior circulation syndrome; D.m.=Diabetes mellitus;
*Stroke etiology according to the TOAST classification [39].
doi:10.1371/journal.pone.0021338.t001
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patients with an unfavorable recovery within 90 days after
admission (defined as a BI score of .=95%) could be observed
as compared to individuals with a favorable outcome (median
MBL levels 1754 vs. 1270 ng/ml, p=0?06), which was significant
in the multivariate analysis (OR 1.26, 95% CI 1.04–1.54, for every
1000 ng/ml increase, p=0.02).
The conservative treatment group consisted of 28/287 (9.8%)
patients with MBL levels below 100 ng/ml, a cut-off generally
accepted for the definition of functional MBL deficiency. Baseline
characteristics were similar in MBL deficient patients as compared
to patients with MBL levels $100 ng/ml with the exception of a
history of hypertension (15/28 vs. 205/259, p=0.004). In this
MBL deficient group there were 19 patients (68%) with a
favorable recovery (i.e., a mRS score of 0 or 1) three months
after admission, five (18%) with an unfavorable outcome (mRS
score of 2–5) and four (14%) individuals who died (mRS score of
6), as compared to 116 (45%), 115 (44%) and 28 (11%)
corresponding patients with MBL levels above 100 ng/ml
(p=0.025, Figure 2A). In a multivariate analysis (including history
of hypertension as a cofactor) MBL deficient patients were subject
to an almost 3-fold decreased risk to suffer from significant
disabilities or to die within three months after ischemic stroke (OR
0.38, 95% CI 0.14–0.98, p=0.046). Besides absence of MBL
deficiency, only older age (OR 1.05, 95% CI 1.02–1.07, for every
year increase, p,0.0001) and more comorbidities (OR 1.22, 95%
CI 1.02–1.46, for every unit increase in the Charlson Comorbidity
index, p=0.03) were independent predictors of an unfavorable
outcome after three months. Analysis of the secondary outcome
measure, the Barthel Index further underscored the beneficial
effect of MBL deficiency in ischemic stroke (p=0.028, Figure 2B).
For the association with mortality alone Kaplan-Meier survival
curves were calculated stratified by MBL tertiles. The risk for
death within three months after admission was lowest in patients in
the first tertile (MBL,542 ng/ml; survival rate 9262.8%),
intermediate in the second (MBL 542–2288 ng/ml; survival rate
8963.1%) and highest in the third tertile (MBL.2288 ng/ml,
survival rate 8663.5%). However, these differences did not reach
statistical significance (p=0.26 for the comparison of the first vs.
third tertile; data not shown).
Association with severity and size of stroke. Patients with
a mild stroke at presentation (defined as a NIHSS score of #7
[25,26]) showed significantly lower MBL levels than individuals
with intermediate or high (8–14 and .14, respectively) NIHSS
scores (median MBL level 1176 (IQR 386–2640) vs. 1893 (IQR
555–3536) ng/ml, p=0.025, Figure 3). Analysis of a subgroup of
patients (n=157 in whom MRI as part of the initial work-up was
available revealed a striking association between lesion size and
MBL serum levels. Median MBL levels were lowest in patients
with a small (,10 ml) lesion (685 (IQR 255–2577) ng/ml) as
compared to patients with medium (10–100 ml) and large
(.100 ml) infarction volumes (1653 (IQR 497–2877) ng/ml and
3826 (IQR 1356–4433) ng/ml, respectively. p=0.0027, Figure 4).
Furthermore, MBL deficient patients (,100 ng/ml) showed
significantly smaller infarctions as compared to MBL sufficient
patients (mean size 0.6 (SD 0.8) vs. 18.4 (SD 43.6) ml, p=0.0025).
Notably, none of the MBL deficient patients experienced a
medium or large cerebral lesion (volume of .10 ml) as compared
to 39 of 140 (28%) patients with MBL levels above 100 ng/ml
(p=0.0073).
After adjustment for covariables being present prior to the
ischemic event only MBL levels remained independently associ-
ated with lesion size on MRI: The average infarction volume
increased by 7.3 ml for every 1000 ng/ml increase in MBL serum
levels (standard error 2.32, 95% CI 2.9–12.2, p=0.002).
Thrombolysis treatment group
In contrast to the conservatively treated group MBL levels did
not influence any of the above mentioned outcome measures in
patients receiving thrombolytic agents after admission. Notably,
median MBL levels were similar in patients with a less severe
(NIHSS score ,7) vs. a severe stroke (NIHSS score .7) at
presentation (1508 vs. 1488 ng/ml, p=0.96), in patients with
small vs. medium/large stroke lesions on MRI (1315 vs. 1482 ng/
ml, p=0.66), in patients with a complete recovery vs. an
unfavorable outcome (1325 vs. 1680, p=0.24) and in patients
surviving vs. dying during a 90-day follow-up (1620 vs. 1341 ng/
ml, p=0.5). This holds also true for the cut-off of ,100 ng/ml,
representing MBL deficient patients.
Pooled analysis
If all study participants (thrombolysis and conservative treat-
ment group) were analyzed together, MBL levels were still
independently associated with an unfavorable outcome three
Figure 1. Association of functional outcome with serum MBL
levels. Conservative treatment group: differences in MBL serum
concentrations according to the functional outcome as assessed by
the modified Rankin Scale 90 days after presentation. Horizontal lines
represent medians.
doi:10.1371/journal.pone.0021338.g001
Table 2. Multivariate Analysis: predictors of an unfavorable
outcome (defined as a score of 2–6 on the modified Rankin
Scale) three months after ischemic stroke.
Multivariate Analysis
Predictor OR 95% CI P-value
MBL levels (increase per 1000 ng/ml) 1.23 1.02–1.48 0.036
Age (increase per year) 1.05 1.03–1.07 ,0.0001
History of prior stroke 1.76 0.96–3.21 0.066
Charlson Comorbidity index (increase per unit) 1.19 0.99–1.42 0.066
Abbreviations: OR=odds ratio; CI=confidence interval.
doi:10.1371/journal.pone.0021338.t002
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(MBL,100 ng/ml) with functional recovery three months after ischemic stroke as assessed by (A) the modified Rankin Scale and (B) the Barthel Index.
doi:10.1371/journal.pone.0021338.g002
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every 1000 ng/ml increase, p=0.019) in addition to only age (OR
1.03, 95% CI 1.02–1.05, for every year increase, p,0.0001).
Furthermore, the association of low MBL levels with smaller
infarction size persisted in the pooled analysis (data not shown).
Discussion
Several lines of evidence have emphasized the pivotal role of the
complement system in general and the MBL pathway in particular
in the pathogenesis of I/R injury, including ischemic stroke
[15,16,17,18,19]. In the present study, we demonstrate that
functional MBL deficiency is associated with smaller cerebral
lesion volumes and favorable outcomes in patients with conser-
vative treatment after acute ischemic stroke but not in patients
receiving i.v. thrombolysis.
These results are in line with data from Cervera et al. who
demonstrated a significant association of genetically defined MBL
deficiency with favorable outcome albeit in a smaller mixed
hemorrhagic and ischemic stroke cohort [15]. By analyzing
infarction size on MRI and comparing outcome measures in a
conservative vs. thrombolytic treatment cohort we highlight in
more detail the potential pathogenetic relevance of the MBL
pathway after human ischemic stroke. In the conservative
treatment group MBL deficiency seems to considerably restrict
propagation of damage after ischemic stroke. Patients with MBL
levels ,100 ng/ml were almost three times more likely to recover
without significant disabilities within three months after admission
when compared to MBL sufficient patients. This protective effect
was even more pronounced when analyzing the association of
MBL levels with infarction volumes on MRI in a subgroup of
patients. Compared to patients with a small cerebral lesion median
MBL serum concentration was more than two-fold and five-fold
higher in patients with medium and large infarction volumes,
respectively. In particular, functionally MBL deficient patients
invariably experienced small cerebral lesions. This is well in line
with experimental data using either MBL-deficient mice or an
inhibitor of the MBL pathway [15,16].
Notably, the magnitude of association was more evident in the
analysis of early infarction volumes than of functional outcome.
Hence, the role of MBL seems to be most prominent in the early
phase of ischemic stroke, whereas functional recovery might not
only be influenced by lesion size and stroke severity (as assessed by
the NIHSS) but several other factors such as age, localization of
infarct, secondary complications, and early initiation of rehabil-
itation services [28]. Alternatively, data from Rahpeyma Y et al.
suggest that complement activation in the brain may not only
exacerbate tissue damage in the acute setting (lesion size) but on
the other hand also promote neurogenesis and regeneration after
ischemia in the long-term (functional outcome) [27].
A significant influence of MBL deficiency on mortality after
ischemic stroke was not evident in our study. Considering that
there were only 32 events in the conservatively treated group
(11%), the study was not powered to analyze smaller differences
between MBL sufficient and deficient patients. Furthermore,
mortality after stroke might be more affected by preexisting
comorbidities and infections than MBL status.
Interestingly, we did not observe a similar protective effect of
MBL deficiency in patients receiving i.v. thrombolysis, which in
theory should more closely mimic experimental I/R injury than
conservative treatment. Several reasons might account for this
important difference. First, our thrombolysis group was rather
small and only powered to detect substantial differences in
outcome, yet results were consistent over all endpoints analyzed.
Second, animal as well as human data assessing the effect of MBL
deficiency on ischemic stroke outcome after systemic thrombolysis
are lacking. Therefore, we a priori chose to separately analyze
Figure 3. Association of stroke severity with serum MBL levels.
Conservative treatment group: differences in MBL serum concentrations
according to stroke severity as assessed by the NIHSS at presentation.
Horizontal lines represent medians.
doi:10.1371/journal.pone.0021338.g003
Figure 4. Association of lesion size with serum MBL levels.
Conservative treatment group: differences in MBL serum concentrations
according to infarction volume on MRI scan (subgroup analysis).
Horizontal lines represent medians. Horizontal dashed line corresponds
to the cut-off of ,100 ng/ml representing MBL deficient patients.
Abbreviation: DWI=Diffusion-weighted imaging.
doi:10.1371/journal.pone.0021338.g004
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ment. In theory, massive systemic complement activation
occurring after thrombolysis might have masked or offset any
favorable effect of MBL deficiency that is usually evident after
experimental cerebral I/R injury [20]. On the other hand, the
benefit of a successful thrombolysis might have significantly
outweighed any effect of the MBL pathway, e.g. by attenuating
inflammatory reaction after ischemic stroke which is only partly
mediated by the MBL pathway. Audebert et al. found that
successful thrombolysis was associated with subsequently lower C-
reactive protein (CRP) and white blood count levels [29].
Moreover, CRP levels were not predictive of functional outcome
in a study of patients receiving thrombolysis [30] in contrast to
several studies involving exclusively or mainly conservatively
treated patients [31,32,33,34], thereby further underscoring the
influence of thrombolysis on inflammation after stroke. In
conclusion, additional prospective trials are warranted to further
investigate the effect of the MBL pathway in patients undergoing
thrombolysis.
Recently, recombinant human C1-Inhibitor has been shown to
function as a powerful inhibitor of MBL and its detrimental
cerebral effects in a mouse model of cerebral I/R injury [16]. By
demonstrating smaller lesion volume and improved functional
outcome in MBL deficient patients the present study draws further
attention to MBL as a promising target for reducing cerebral I/R
injury and supports the investigation of functional MBL inhibition
in human ischemic stroke, especially in patients who do not qualify
for thrombolytic treatment.
Despite the precisely characterized cohort the present prospec-
tive observation study has limitations including the post hoc
analysis of MBL serum levels. Furthermore, MRI testing was not
available for all patients in both groups, which may have biased
results. Yet, analysis of functional outcome in patients with MRI
data revealed similar effect of MBL deficiency as compared to the
whole cohort (data not shown). Regarding the thrombolysis group
the small sample size limits the significance of the observed data.
At first sight the fact that MBL2 genotypes were not determined
could appear as a limitation. However, MBL serum levels show
little variation throughout life. In particular, MBL levels have
never been shown to strongly fluctuate during acute diseases, and
MBL levels in our patients were not influenced by the interval
from symptom onset to presentation and blood sampling in our
emergency department. Therefore, measurement of MBL serum
levels by ELISA allows reliable quantification of the functional
activity of the MBL pathway in vivo in this setting [35]. When
evaluating associations with diseases measurement of MBL serum
levels might in fact represent a more sensitive approach than
determination of genotypes as individuals with the same genotype
may vary up to tenfold in MBL serum levels [5,36,37]. Moreover,
MBL2 genotyping cannot account for the significant changes of
MBL serum levels induced by thyroid dysfunction [38].
In conclusion, functional MBL deficiency was associated with
smaller infarction volume and favorable functional outcome in
patients receiving conservative treatment after acute ischemic
stroke. These findings support the concept of a significant
contribution of the MBL pathway to cerebral tissue injury in
human ischemic stroke. Thus, transient and early blockade of
MBL or inhibition of the lectin complement pathway may
represent a therapeutically promising strategy for reducing I/R
associated cerebral damage.
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